|
gptkbp:instanceOf
|
gptkb:United_States_federal_law
|
|
gptkbp:abbreviation
|
gptkb:FDASIA
|
|
gptkbp:affects
|
gptkb:Food_and_Drug_Administration
|
|
gptkbp:category
|
gptkb:Health_law
Pharmaceutical law
Medical device law
|
|
gptkbp:containsProvision
|
reauthorization of Generic Drug User Fee Amendments (GDUFA)
reauthorization of Biosimilar User Fee Act (BsUFA)
reauthorization of Prescription Drug User Fee Act (PDUFA)
reauthorization of Medical Device User Fee Amendments (MDUFA)
|
|
gptkbp:enactedBy
|
gptkb:United_States_Congress
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Public Law 112-144
|
|
gptkbp:legislature
|
gptkb:112th_United_States_Congress
|
|
gptkbp:officialName
|
gptkb:Food_and_Drug_Administration_Safety_and_Innovation_Act
|
|
gptkbp:publicLawNumber
|
112-144
|
|
gptkbp:purpose
|
to enhance the safety of the drug supply chain
to promote innovation in medical products
to reauthorize and expand the user fee programs for prescription drugs and medical devices
|
|
gptkbp:signedBy
|
gptkb:Barack_Obama
2012-07-09
|
|
gptkbp:statutesAtLargeCitation
|
gptkb:126_Stat._993
|
|
gptkbp:bfsParent
|
gptkb:Food_and_Drug_Administration_Safety_and_Innovation_Act
|
|
gptkbp:bfsLayer
|
6
|